Read More

Clearside Biomedical Announces Pricing Of $15M Registered Direct Offering With Institutional Investors And An Existing Stockholder, Providing For The Purchase And Sale Of 11,111,111 Shares Of Common Stock And Accompanying Warrant

Clearside Biomedical, Inc. ("Clearside" or the "Company") (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®),

CLSD